Richard Mole Appointed President and Chief Executive Officer of Boehringer Ingelheim (Canada) Ltd.

Burlington, Ontario – Boehringer Ingelheim, one of the world’s top 15 pharmaceutical companies, announced the appointment of Richard Mole as President and Chief Executive Officer of Boehringer Ingelheim (Canada) Ltd. In this role, Mr. Mole assumes responsibility for the company’s Prescription Medicine business in Canada and provides oversight to the Animal Health and Consumer Health Care business units.

Mr. Mole brings more than 24 years of experience in the pharmaceutical industry. He joined Boehringer Ingelheim in 1996 and most recently served as Corporate Vice President, Prescription Medicine and Consumer Health Care for Boehringer Ingelheim’s Latin American region, overseeing the pharmaceutical operations in the 11 Latin American countries as well as in Central America.

Throughout his tenure with Boehringer Ingelheim, Mr. Mole has held various positions in Europe and Latin America, including Head of Prescription Medicine in Spain and Argentina and area management responsibility for the U.S. Prescription Medicine business. Mr. Mole holds a Master of Science degree in Chemical Physics and a Bachelor of Science degree in Chemistry, both from the University of Kent.

“I am excited to join Boehringer Ingelheim’s Canadian operation given the opportunities we have across all three of our business units to bring important and potentially life-changing treatment options to Canadian patients in need,” said Mr. Mole. 

About Boehringer Ingelheim (Canada) Ltd.
The Boehringer Ingelheim group is headquartered in Ingelheim, Germany, and operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed the development of innovative, cost-effective medicines and finding medical breakthroughs for therapies, which fulfill unmet medical needs.

Our drug discovery focuses on six major therapeutic areas:  respiratory diseases, cardio-metabolic diseases, oncology, neurological diseases, immunology and inflammation, and infectious diseases.

The Canadian headquarters of Boehringer Ingelheim was established in 1972 in Montreal, Quebec and is now located in Burlington, Ontario. Boehringer Ingelheim employs more than 550 people across Canada. For more information please visit www.boehringer-ingelheim.ca.